Navigation Links
United States Patent Office Grants CryoCor's Request for Patent Interference
Date:2/13/2008

CryoCor Named Senior Party in Interference

SAN DIEGO, Feb. 13 /PRNewswire-FirstCall/ -- CryoCor, Inc. (Nasdaq: CRYO), a medical device company focused on the treatment of cardiac arrhythmias, announced today that the United States Patent and Trademark Office (USPTO) has declared a patent interference between a patent application exclusively licensed by CryoCor and two patents held by CryoCath Technologies Inc. A patent interference is an administrative proceeding within the USPTO to establish which party was the first to invent certain subject matter and, therefore, should have patent rights to the technology. The patent interference is related to certain pre-cooling technologies that CryoCor considers important to CryoCath's cryoablation system.

The USPTO designated CryoCor to be the senior party in the interference as its patent application was found to predate CryoCath's original patent applications. In an interference proceeding, the burden of proof is on the junior party (in this case, CryoCath) to establish an earlier date of invention. The interference dispute will be determined by the Board of Patent Appeals and Interferences and presided over by an Administrative Patent Judge. The proceedings are scheduled to begin in March 2008 and the Company expects a final judgment to be made in 2009. CryoCor reported that a second interference, also in the field of pre-cooling, is anticipated to be declared by the USPTO in the first half of 2008.

Ed Brennan, Ph.D., President and Chief Executive Officer of CryoCor, said, "We are very pleased with USPTO's decision to grant CryoCor's request to declare this interference, and we anticipate a second interference between CryoCor and CryoCath to be declared in the near future. We believe we have broad coverage in our patent portfolio covering pre-cooling, which we consider important for a cryoablation system. These patent interferences are an important part of our strategy to secure our intellectual property position in the field of cryoablation."

About CryoCor

CryoCor is a medical technology company that has developed and manufactures a disposable catheter system based on its proprietary cryoablation technology for the minimally invasive treatment of cardiac arrhythmias. The Company's product, the CryoCor Cardiac Cryoablation System, or the Cryoablation System, is designed to treat cardiac arrhythmias through the use of cryoenergy, or extreme cold, to destroy targeted cardiac tissue. The Cryoablation System has been approved in Europe for the treatment of atrial fibrillation, and atrial flutter, the two most common and difficult to treat arrhythmias, since 2002. In the United States, CryoCor is conducting a pivotal trial to evaluate the safety and efficacy of the Cryoablation System for the treatment of atrial fibrillation and the Cryoablation System has been approved for the treatment of right atrial flutter. For more information please visit the Company's website at http://www.cryocor.com.

Forward Looking Statements

The statements in this press release that are not descriptions of historical facts are forward-looking statements that are subject to risks and uncertainties. These include statements related to the merits of CryoCor's positions in its interference proceedings with CryoCath and the possible outcome of those proceedings, the likelihood of a second interference being declared and the value of pre-cooling technology in a cryoablation system, and specifically, CryoCath's cryoablation system, all of which are prospective. Such statements are only predictions and reflect CryoCor's expectations and assumptions as of the date of this press release based on currently available operating, financial, and competitive information. The actual events or results may differ materially from those projected in such forward-looking statements due to a number of factors, including risks involved with CryoCor's technology; risks associated with the Company's dependence on patents and proprietary rights; risks associated with the Company's protection and enforcement of its patents and proprietary rights; risks associated with the development or availability of competitive products or technologies and the other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company expressly disclaims any intent or obligation to update any of these forward-looking statements.

Contact:

CryoCor, Inc. The Ruth Group

Gregory J. Tibbitts Nick Laudico / Zack Kubow (investors)

Chief Financial Officer (646) 536-7030 / 7020

(858) 909-2200 nlaudico@theruthgroup.com

gtibbitts@cryocor.com zkubow@theruthgroup.com

Jason Rando (media)

(646) 536-7025

jrando@theruthgroup.com


'/>"/>
SOURCE CryoCor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. United Therapeutics to Announce Fourth Quarter and Annual 2007 Financial Results Before Market Open on Tuesday, February 19, 2008
2. Energy Conversion Devices and United Solar Ovonic Enter Into New $55 Million Secured Credit Facility Agreements
3. Nycomeds Ciclesonide to be Commercialised in the United States by Sepracor
4. Chindexs United Family Hospitals and Clinics and NBC Enter into Healthcare Services Agreement
5. Neptune Technologies receives GRAS notification in the United States
6. Essilor: New Acquisitions in the United States and Brazil
7. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
8. Medical Services Begins Working With United States Companies for Distribution of Its Products
9. United Therapeutics Reports Third Quarter 2007 Financial Results
10. Bioponic Phytoceuticals to Roll Out Multiple Products to 1,000 Major Health Food Stores in the Western United States
11. ISTO Technologies Granted Key Patent for Cartilage Cell Expansion by the United States Patent Office
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, has ... The bold new look is part of a transformation to increase awareness, appeal to ... period. , It will also expand its service offering from its signature gourmet cooking ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
Breaking Biology Technology:
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):